Manufacturing
Pharmaceutical manufacturing is rapidly advancing with automation and AI, boosting efficiency and throughput. Industry experts discuss these opportunities and the challenges of implementation and standardization. We also look at how novel solutions can help cell and gene therapy manufacturers reduce costs, improve scalability, and optimize processes, enhancing both clinical profiles and commercial viability.
Pharmaceutical manufacturing is developing at a lightning pace as the confluence of automation and AI creates opportunities for much higher efficiency and throughput. Experts from across the industry discuss these, and the challenges around implementation and standardization.
Experts working in the advanced therapy sector tell In Vivo how novel solutions can empower cell and gene therapy manufacturers to reduce costs, improve scalability and optimize their processes – improving the clinical profile and commercial viability of products.
Industry veteran Miguel Forte navigates new kid on the block Kiji Therapeutics into the clinic to prove cell therapy manufacturing doesn’t need to decelerate commercial viability.
Chimeric antigen receptor T-cell (CAR-T) therapies have revolutionized the treatment of blood cancer, but scalability remains a major challenge. Experts explain how technologies such as chip-based miniaturized models and automation could be part of the solution.